
## INTERNATIONAL SEARCH REPORT

3/00617 PCT/S



### A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 473/20, C07D 473/22, A61K 31/52, A61K 31/522, A61P 25/28, A61P 35/00 According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## CHEM. ABS. DATA, BIOSIS, EMBASE, MEDLINE, EPO-INTERNAL


## C. DOCUMENTS CONSIDERED TO BE RELEVANT

WO 9618400 A1 (EUROCELTIQUE S.A.), 20 June 1996 (20.06.96), Thioxanthines for use in the treatment of asthma, inflammation and dementia; page 5, lines 23-25; pages 6-7;	1-12
especially the compounds in claims 7 and 9, page 29 and in the claim 17, page 31	1-12
~~	
EP 01016407 A1 (KYOWA HAKKO KOGYO CO., LTD.), 5 July 2000 (05.07.00), (8-styryl-substituted 2, 6-dioxo analogues; neural degeneration; adenosin A2-antagonists)	1-12
<b></b>	
	(20.06.96), Thioxanthines for use in the treatment of asthma, inflammation and dementia; page 5, lines 23-25; pages 6-7;  especially the compounds in claims 7 and 9, page 29 and in the claim 17, page 31  EP 01016407 A1 (KYOWA HAKKO KOGYO CO., LTD.), 5 July 2000 (05.07.00), (8-styryl-substituted 2, 6-dioxo analogues; neural degeneration; adenosin

X	Further documents are listed in the continuation of Box	C.	See patent family annex.		
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority		
"A"	document defining the general state of the art which is not considered to be of particular relevance		date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date	"X"	considered novel or cannot be considered to involve an inventive		
"L"	document which may throw doubts on priority claim(s) or which is		step when the document is taken alone		
}	cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is		
<b>"O"</b>	document referring to an oral disclosure, use, exhibition or other means		combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"P"	document published prior to the international filing date but later than the priority date claimed	<b>"&amp;</b> "	document member of the same patent family		
Dat	e of the actual completion of the international search	Date	of mailing of the international search report		
ļ	-		<b>0 5 -08-</b> 2003		
4	4 August 2003				
Nar	Name and mailing address of the ISA/		Authorized officer		
	edish Patent Office		•		
Box	x 5055, S-102 42 STOCKHOLM	PER	RENSTÖM/BS		
Fac	simile No. +46 8 666 02 86	Telep	hone No. +46 8 782 25 00		

	PC1/3E U3/1	50017
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0430300 A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 5 June 1991 (05.06.91), (7-(4-arylbenzyl)-substituted analogues, see especially Ref. Ex. No. 45 in Table 2a on page 15; stroke; angiotensin II antagonists)	1-12
-	4000 (05 05 00)	1.10
A	US 5756511 A (WEST ET AL), 26 May 1998 (26.05.98), (1-substituted 2,6-dioxo analogues; Alzheimer's Disease; APP inhibitors)	1-12
	. <b></b>	
A	US 5173491 A (KAMOUN ET AL), 22 December 1992 (22.12.92),	1-12
	(8-diethylaminocarbonylpiperazinopropyl 2,6-dioxo analogue; Alzheimer's Disease)	3
•	UO 010T14C A1 (ASTDATENECA AD) 15 November 2001	1-12
Α .	WO 0185146 A1 (ASTRAZENECA AB), 15 November 2001 (15.11.01), (Previously known MPO inhibitors)	1-12
A	WO 9936073 A1 (CELL THERAPEUTICS, INC.), 22 July 1999 (22.07.99), (1-substituted 2,6-dioxo analogues; inflammation; Interleukin-12 inhibitors)	1-12
		·

## INTERNATIONAL SEARCH REPORT



Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	mational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. 🔀	Claims Nos.: 7 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  see next sheet
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

#### INTERNATIONAL SEARCH REPORT



The initial phase of the search revealed a very large number of documents potentially relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of claim 7 may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim is impossible. Consequently, the search regarding the first medical indication has been restricted to a very small sample of the large number of documents found, as well as the compounds listed in the present claim 8.

# INTERNATIONAL RCH REPORT Information on pater anily members

26/07/03

Internationa lication No.
PCT/SE 03/00617

Patent document Publication cited in search report date		Patent family member(s)		Publication date		
WO	9618400	A1	20/06/96	AU CA EP IL JP US US	4527996 A 2206804 A,C 0799040 A 116382 D 2001523213 T 5977119 A 6025361 A 6268373 B	03/07/96 20/06/96 08/10/97 00/00/00 20/11/01 02/11/99 15/02/00 31/07/01
EP	01016407	A1	05/07/00	NONE		
EP	0430300	A2	05/06/91	CA JP	2031328 A 3223284 A	02/06/91 02/10/91
บร	5756511	Α	26/05/98	NONE		,
US	5173491	A	22/12/92	AT AU CA DE DK EP SE ES FR HK IE JP NZ OA ZA	105478 T 631679 B 6322890 A 2026118 A,C 69008853 D,T 470317 T 0470317 A,B 0470317 T3 2056415 T 2665636 A,B 56997 A 65158 B 1920856 C 4095029 A 6047539 B 235389 A 9464 A 9007739 A	15/05/94 03/12/92 14/05/92 11/02/92 13/10/94 19/09/94 12/02/92 01/10/94 14/02/92 09/05/97 04/10/95 07/04/95 27/03/92 22/06/94 23/12/91 15/11/92 31/07/91
WO	0185146	A1	15/11/01	AU CA CN EP GB GB	6088001 A 2406512 A 1427718 T 1294366 A 0011358 D 2362101 A	20/11/01 15/11/01 02/07/03 26/03/03 00/00/00 14/11/01
WO	9936073	A1	22/07/99	. AU US US	2098799 A 6469017 B 2002028823 A	02/08/99 22/10/02 07/03/02